Dmitry Balyasny’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-148,684
| Closed | -$29.3M | – | 3006 |
|
|
2026
Q1 | $29.3M | Sell |
148,684
-390,506
| -72% | -$75.3M | 0.04% | 536 |
|
|
2025
Q4 | $99.1M | Buy |
539,190
+201,109
| +59% | +$35.3M | 0.13% | 179 |
|
|
2025
Q3 | $51.9M | Buy |
338,081
+154,189
| +84% | +$23.3M | 0.07% | 356 |
|
|
2025
Q2 | $25.7M | Sell |
183,892
-225,100
| -55% | -$31.5M | 0.04% | 565 |
|
|
2025
Q1 | $60.1M | Buy |
408,992
+82,158
| +25% | +$11.9M | 0.1% | 249 |
|
|
2024
Q4 | $42.8M | Buy |
326,834
+319,590
| +4,412% | +$44.7M | 0.06% | 371 |
|
|
2024
Q3 | $1.13M | Sell |
7,244
-352,758
| -98% | -$56.9M | ﹤0.01% | 1914 |
|
|
2024
Q2 | $56.2M | Buy |
360,002
+174,598
| +94% | +$26.3M | 0.1% | 263 |
|
|
2024
Q1 | $25.1M | Buy |
+185,404
| New | +$24.6M | 0.04% | 532 |
|
|
2023
Q4 | – | Sell |
-3,035
| Closed | -$411K | – | 2487 |
|
|
2023
Q3 | $411K | Sell |
3,035
-148,054
| -98% | -$20.2M | ﹤0.01% | 1812 |
|
|
2023
Q2 | $21.6M | Buy |
+151,089
| New | +$22.2M | 0.05% | 497 |
|
|
2022
Q3 | – | Sell |
-244,817
| Closed | -$32.4M | – | 2839 |
|
|
2022
Q2 | $32.4M | Buy |
+244,817
| New | +$32.1M | 0.11% | 268 |
|
|
2022
Q1 | – | Sell |
-100,599
| Closed | -$11.7M | – | 2468 |
|
|
2021
Q4 | $11.7M | Buy |
+100,599
| New | +$11.8M | 0.04% | 591 |
|
|
2021
Q1 | – | Sell |
-119,799
| Closed | -$12M | – | 1748 |
|
|
2020
Q4 | $12M | Buy |
+119,799
| New | +$12.7M | 0.07% | 398 |
|
|
2020
Q3 | – | Sell |
-482,849
| Closed | -$51.1M | – | 1282 |
|
|
2020
Q2 | $51.1M | Buy |
482,849
+197,475
| +69% | +$20.4M | 0.44% | 39 |
|
|
2020
Q1 | $25.5M | Buy |
285,374
+20,499
| +8% | +$1.93M | 0.3% | 78 |
|
|
2019
Q4 | $26.4M | Buy |
264,875
+107,067
| +68% | +$10.1M | 0.16% | 199 |
|
|
2019
Q3 | $14.1M | Buy |
157,808
+10,185
| +7% | +$883K | 0.1% | 313 |
|
|
2019
Q2 | $12.2M | Buy |
147,623
+107,040
| +264% | +$8.39M | 0.08% | 354 |
|
|
2019
Q1 | $3.28M | Sell |
40,583
-283,284
| -87% | -$22.3M | 0.02% | 684 |
|
|
2018
Q4 | $24.6M | Sell |
323,867
-246,764
| -43% | -$19.3M | 0.18% | 161 |
|
|
2018
Q3 | $45.2M | Buy |
570,631
+37,020
| +7% | +$2.8M | 0.21% | 120 |
|
|
2018
Q2 | $37.5M | Buy |
533,611
+49,508
| +10% | +$3.56M | 0.17% | 151 |
|
|
2018
Q1 | $33.9M | Buy |
484,103
+7,807
| +2% | +$541K | 0.14% | 201 |
|
|
2017
Q4 | $33.1M | Sell |
476,296
-391,830
| -45% | -$26.4M | 0.1% | 255 |
|
|
2017
Q3 | $58.8M | Buy |
868,126
+855,576
| +6,817% | +$54.1M | 0.23% | 106 |
|
|
2017
Q2 | $856K | Sell |
12,550
-400,541
| -97% | -$26.2M | ﹤0.01% | 1143 |
|
|
2017
Q1 | $25.7M | Sell |
413,091
-327,063
| -44% | -$19M | 0.12% | 227 |
|
|
2016
Q4 | $40.4M | Buy |
+740,154
| New | +$42M | 0.22% | 126 |
|
|
2015
Q1 | – | Sell |
-63,280
| Closed | -$4.45M | – | 942 |
|
|
2014
Q4 | $4.45M | Buy |
+63,280
| New | +$4.53M | 0.04% | 458 |
|
|
2013
Q4 | – | Sell |
-495,013
| Closed | -$25.7M | – | 489 |
|
|
2013
Q3 | $25.7M | Buy |
+495,013
| New | +$24.9M | 0.35% | 63 |
|
Other funds holding AZN
EP
IA
Dmitry Balyasny's AZN Position: Q2 2026 in Review
Dmitry Balyasny sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 148,684 shares — an estimated $29.3M sold.
Dmitry Balyasny first reported a position in AZN in Q3 2013 and held it in 31 quarters. The position peaked at $99.1M in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Dmitry Balyasny reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
- Dmitry Balyasny sold 148,684 AstraZeneca shares in Q2 2026, an estimated $29.3M.
- Dmitry Balyasny first reported a position in AstraZeneca in Q3 2013 and held it in 31 quarters.
- Dmitry Balyasny's AstraZeneca position peaked at $99.1M in Q4 2025.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.